Haematology

News

AbbVie, Genmab eye label expansion for Epkinly

Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.

News

Nkarta tweaks regimen in bid to revive AML programme

Last year, Nkarta was celebrating data which showed that its natural killer (NK) cell therapy for acute myeloid leukaemia (AML) was showing remarkable efficacy in hard-to-

Oncology

ASCO 2023 – Martin Vogel and Edmond Chan

In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.

News

FDA sets Dec deadline for Vertex, CRISPR sickle cell therapy

The FDA has started a priority review of Vertex Pharma and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel) in sickle cell disease (SCD), with a decision on approva

News

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibro

News

Leaked data shows stellar efficacy for J&J’s Carvykti

Johnson & Johnson was preparing to divulge the data from its eagerly-awaited CARTITUDE-4 trial of CAR-T therapy Carvykti later this year, but a leak of the data has gi

AbbVie, Genmab eye label expansion for Epkinly

Nkarta tweaks regimen in bid to revive AML programme

ASCO 2023 – Martin Vogel and Edmond Chan

FDA sets Dec deadline for Vertex, CRISPR sickle cell therapy

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

Leaked data shows stellar efficacy for J&J’s Carvykti

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Haematology

Editor's Picks